

CHEVAL-in: neurophysiological determinants of conversion to psychosis and response to cholinesterase inhibitors in Parkinson's disease

<https://neurodegenerationresearch.eu/survey/cheval-in-neurophysiological-determinants-of-conversion-to-psychosis-and-response-to-cholinesterase-inhibitors-in-parkinsons-disease/>

Principal Investigators

dr. E.M.J. Foncke

Institution

Vumc

Contact information of lead PI

Country

Netherlands

Title of project or programme

CHEVAL-in: neurophysiological determinants of conversion to psychosis and response to cholinesterase inhibitors in Parkinson's disease

Source of funding information

Parkinson Vereniging

Total sum awarded (Euro)

€ 39,609

Start date of award

01/12/2015

Total duration of award in years

1

Keywords

Research Abstract

Visual hallucinations (VH) are the most common non-motor symptoms in Parkinson's disease (PD). As an independent predictor for cognitive decline and nursing home placement they form an important disability milestone in the

course of PD. According to current clinical guidelines minor VH do not require treatment per se. But as minor VH precede the stage of major VH without insight and PD associated psychosis (PDP) they offer an opportunity for early intervention. Neuroleptic drugs delay the transition into PDP but are unsuitable for early treatment of VH due to their side effects. We hypothesize that cholinesterase inhibitors (ChEI) are a well-tolerated alternative for the early treatment of minor VH to delay the progression to PDP and that brain network analysis is suitable to predict treatment response.

Objective of the study:

investigate whether early treatment with ChEI delays the progression of minor VH to major VH without insight or PDP. In addition, we will measure motor control, psychotic symptoms, cognitive impairment, mood disorders, adverse events and compliance, disability, caregiver burden and care use. We assess the cost-effectiveness of early chronic treatment of VH with ChEI. Finally, we analyse changes of functional brain networks before and during treatment.

Study design:

a randomized, double blind, placebo-controlled, multi-center trial with an economic evaluation.

Study population:

168 patients with PD and VH after fulfilling the in-and exclusion criteria.

Further information available at:

https://www.toetsingonline.nl/to/ccmo_search.nsf/fABRpop?readform&unids=B1190B25CAC6E1I

Types:

Investments < €500k

Member States:

Netherlands

Diseases:

N/A

Years:

2016

Database Categories:

N/A

Database Tags:

N/A